All In Biotech

Drug Trial Radar · NCT02432144

A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)

A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7

Last checked: Nov 20, 2026Latest source record: Jul 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12

Actual

Start

Nov 10, 2015

Primary completion

Jan 14, 2019

Study completion Jan 14, 2019

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
May 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the long-term safety of UX003 in subjects with MPS 7.

Conditions

  • Sly Syndrome
  • MPS VII
  • Mucopolysaccharidosis
  • Mucopolysaccharidosis VII

Interventions

  • UX003Drug

    solution for intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to DiscontinuationTime frame: From first dose of study drug until 30 days after the last dose of study drug. Mean duration of UX003 treatment was 100.5 weeks.

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Children's Hospital Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • University of Minnesota

    Minneapolis, Minnesota

  • Baylor College of Medicine

    Houston, Texas

  • Hospital Infantil Candido Fontoura Sao Paulo

    São Paulo, Brazil

  • Centenario Hospital Miguel Hidalgo, Pediatrics

    Aguascalientes, Mexico

  • Unidade de Doenças Metabólicas - Centro Hospitalar do Porto

    Porto, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.